Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.22 USD | +2.39% | -11.27% | -51.45% |
10/05 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
10/05 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.45% | 2.46B | |
+28.90% | 49.18B | |
+1.10% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.74% | 26.09B | |
-22.16% | 18.71B | |
+7.91% | 13.26B | |
+32.27% | 12.32B | |
-0.49% | 11.99B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc., Q3 2022 Earnings Call, Nov 02, 2022